THRIVE-CAR-T digital app for CAR-T patients
This trial tests a digital app to support patients receiving CAR-T therapy. It may help you track symptoms and communicate with your care team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can understand English
- You have a blood cancer (like leukemia, lymphoma, or myeloma)
- You are getting CAR-T therapy at Massachusetts General Hospital (MGH) with an FDA-approved product
- You do not have severe memory or thinking problems that would make using the app difficult
- You are not already in another supportive care study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a digital health app to help you manage symptoms and stay connected with your care team while receiving CAR-T therapy as an outpatient. It's designed for people with blood cancers who have a caregiver living with them.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.